U.S. Pain Foundation was among several hundred organizations and individuals to weigh in on a recent Food and Drug Administration (FDA) comment period. Specifically, the FDA asked for the public’s views on two main issues:
- What criteria the FDA should use to evaluate new opioids to treat pain
- What new incentives are needed to better support and encourage the development of new treatments for pain
The comment period came on the heels of a Sept. 17 public hearing at the FDA on these same topics.
U.S. Pain notified its community of the comment period, which ended Nov. 18, via email, social media, and an op-ed by Cindy Steinberg published in National Pain Report.
To read U.S. Pain Foundation’s official letter to the FDA, click here. To get notifications about comment periods like these straight to your inbox, sign up as a U.S. Pain Foundation advocate.